Ogsiveo™ (nirogacestat) 50 mg tablets

Please join us for a presentation on:

OGSIVEO™ (nirogacestat), the first and only FDA-approved therapy for adult patients with progressing desmoid tumors who require systemic treatment

PROGRAM DETAILS

Thursday, June 20, 2024
6:00 PM Pacific Daylight Time Presentation
Fogo de Chao
377 Santana Row #1090
San Jose , CA 95128

PRESENTED BY

Noah Federman, MD
Medical Director: Clinical Translational Research Center;
Director: Pediatric Bone and Soft Tissue Program
UCLA Health
Los Angeles, CA

Use the link below to register for this event
https://www.swtxspeakerprograms.com/attendee

If you have questions about the event, you can contact your SpringWorks Therapeutics representative, Mackenzie Burke at mackenzie.burke@springworkstx.com or +1 925-785-4672

If you have registration questions, you can email springworks@bcdme.com

Indication

OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **Diarrhea:** Diarrhea occurred in 84% of patients treated with OGSIVEO. Grade 3 events occurred in 16% of patients. Monitor patients and manage using antidiarrheal medications. Modify dose as recommended.
- **Ovarian Toxicity:** Female reproductive function and fertility may be impaired in patients treated with OGSIVEO. Impact on fertility may depend on factors like duration of therapy and state of gonadal function at time of treatment. Long-term effects on fertility have not been established. Advise patients on the potential risks for ovarian toxicity before initiating treatment. Monitor patients for changes in menstrual cycle regularity or the development of symptoms of estrogen deficiency, including hot flashes, night sweats, and vaginal dryness.
- **Hepatotoxicity:** ALT or AST elevations occurred in 30% and 33% of patients, respectively. Grade 3 ALT or AST elevations (>5 × ULN) occurred in 6% and 2.9% of patients. Monitor liver function tests regularly and modify dose as recommended.
- **Non-Melanoma Skin Cancers:** New cutaneous squamous cell carcinoma and basal cell carcinoma occurred in 2.9% and 1.4% of patients, respectively. Perform dermatologic evaluations prior to initiation of OGSIVEO and routinely during treatment.
- **Electrolyte Abnormalities:** Decreased phosphate (65%) and potassium (22%) occurred in OGSIVEO-treated patients. Phosphate <2 mg/dL occurred in 20% of patients. Grade 3 decreased potassium occurred in 1.4% of patients. Monitor phosphate and potassium levels regularly and supplement as necessary. Modify dose as recommended.
- **Embryo-Fetal Toxicity:** Oral administration of nirogacestat to pregnant rats during the period of organogenesis resulted in embryo-fetal toxicity at maternal exposures below human exposure at the recommended dose of 150 mg twice daily. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use effective contraception during treatment with OGSIVEO and for 1 week after the last dose.

ADVERSE REACTIONS

- The most common (≥15%) adverse reactions were diarrhea, ovarian toxicity, rash, nausea, fatigue, stomatitis, headache, abdominal pain, cough, alopecia, upper respiratory tract infection, and dyspnea.
- Serious adverse reactions occurring in ≥2% of patients were ovarian toxicity (4%).
- The most common laboratory abnormalities (≥15%) were decreased phosphate, increased urine glucose, increased urine protein, increased AST, increased ALT, and decreased potassium.

DRUG INTERACTIONS

- **CYP3A Inhibitors and Inducers:** Avoid concomitant use with strong or moderate CYP3A inhibitors (including grapefruit products, Seville oranges, and starfruit) and strong or moderate CYP3A inducers.
- **Gastric Acid Reducing Agents:** Avoid concomitant use with proton pump inhibitors and H2 blockers. If concomitant use cannot be avoided, OGSIVEO can be staggered with antacids (e.g., administer OGSIVEO 2 hours before or 2 hours after antacid use).
- Consult the full Prescribing Information prior to and during treatment for important drug interactions.

Please click here for full Prescribing Information.

This Program is conducted by SpringWorks Therapeutics, Inc. No CME credits are available. In accordance with the PhRMA Code on interactions with Healthcare Professionals, this program is limited to healthcare professionals and persons with bona fide professional interest in the information presented. Therefore, attendance at this Program by guests or spouses is not permitted, unless they would qualify as an appropriate attendee on their own. Please note that the value of any meal provided in connection with the Program will be reported in accordance with federal and state laws and regulations.

SpringWorks THERAPEUTICS